Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bristol Myers Squibb : Celgene Deal Clears A Hurdle

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/15/2019 | 02:48am EDT

By Jared S. Hopkins

Bristol-Myers Squibb shareholders on Friday approved the company's $74 billion acquisition of rival Celgene Corp., looking past an unsuccessful activist campaign to break up the deal.

The deal, first announced Jan. 3, passed with more than 75% of shareholders voting in favor of it. About 24% of shareholders voted against the deal, with less than 1% abstained. A majority of the shares voted were needed for approval. The deal is expected to be completed in the third quarter this year.

The combined company will have nearly $38 billion in annual sales and command a leading position in the $123 billion world-wide market for cancer drugs.

New York-based Bristol pioneered the development of cancer drugs known as immunotherapies, which unleash the body's immune system on tumors. Summit, N.J.-based Celgene leads in the sale of treatments for multiple myeloma.

On Friday morning, shares of Bristol-Myers were down slightly at $45.46, while Celgene shares were down slightly at $94.09.

Serious challenges for the combined company lie ahead. Bristol faces heavy competition from Merck & Co. for immunotherapy sales, while Celgene's top-selling product, multiple myeloma treatment Revlimid, is expected to lose U.S. patent protection in the next several years.

Bristol-Myers Chief Executive Giovani Caforio said after the vote that he would continue to work with all shareholders. He declined to comment on how the 24% no votes compared with other deals because each deal is unique. But he said he was pleased to have support of more than three-quarters of shareholders.

"I believe that is an important endorsement," he said. "At the same time, I do not minimize the fact that some shareholders had expressed concerns about the deal."

Mr. Caforio said he is encouraged that since the deal's announcement three treatments in Celgene's pipeline have been submitted for approval with the Food and Drug Administration. He said he also is confident because of two legal proceedings related to Celgene's top-selling drug, Revlimid. Criticism of the deal was tied in part to the approaching loss of exclusivity for the drug, which generates about two-thirds of Celgene's revenue.

Given the risks, Bristol-Myers shareholders were cool on the deal when it was announced in January, driving the company's stock down 14%.

Then in February, hedge fund Starboard Value LP voiced opposition to the combination and moved to install its own set of directors.

Boston-based investment firm Wellington Management Co. also publicly opposed the deal. A handful of other shareholders also expressed displeasure, including the fifth-largest shareholder, Dodge & Cox, The Wall Street Journal reported.

Wellington has a stake of 7.2% in Bristol-Myers, according to FactSet, but doesn't control the votes on most of those shares. And Starboard dropped its fight after a thumbs-up from Institutional Shareholders Services Inc. and Glass Lewis & Co.

Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY 1.75% 45.4 Delayed Quote.-12.81%
CELGENE CORPORATION 0.72% 93.76 Delayed Quote.45.31%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB COMPA
11:42aBRISTOL MYERS SQUIBB : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
AQ
08:07aBRISTOL MYERS SQUIBB CO : Results of Operations and Financial Condition, Financi..
AQ
07:16aBristol's Opdivo, Eliquis Lift Results Ahead of Celgene Deal
DJ
07:11aBRISTOL MYERS SQUIBB : Myers profit slightly tops Wall Street view on blood thin..
RE
07:10aBRISTOL-MYERS : 1Q Earnings Snapshot
AQ
07:00aBRISTOL MYERS SQUIBB : Reports First Quarter Financial Results
BU
04/17BRISTOL MYERS SQUIBB CO : Other Events, Financial Statements and Exhibits (form ..
AQ
04/17BRISTOL-MYERS SQUIBB COMPANY : Announces Commencement of Exchange Offers and Con..
BU
04/16BRISTOL MYERS SQUIBB : FameWave Announces Clinical Collaboration with Bristol My..
AQ
04/16BRISTOL MYERS SQUIBB : Thumbs-up on $74B BMS-Celgene deal ends months of activis..
AQ
More news
Financials ($)
Sales 2019 24 007 M
EBIT 2019 6 957 M
Net income 2019 6 759 M
Finance 2019 4 994 M
Yield 2019 3,62%
P/E ratio 2019 11,21
P/E ratio 2020 10,66
EV / Sales 2019 2,88x
EV / Sales 2020 2,61x
Capitalization 74 051 M
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 57,9 $
Spread / Average Target 28%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Johanna Mercier President & Head-US Commercial
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-12.81%74 051
JOHNSON & JOHNSON8.41%372 522
ROCHE HOLDING LTD.9.68%227 039
PFIZER-9.69%218 852
NOVARTIS7.44%195 750
MERCK AND COMPANY-2.20%192 697